 |
1kits（10Vials）
| Quantity: | |
|---|---|
▎Cortagen Research
Molecular Background
Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide that was obtained through directed synthesis by a team led by Russian scholar V. Kh. Khavinson, based on an amino acid analysis of the cerebral cortex peptide preparation Cortexin[1].
Research Progress
In research by I. V. Zarubina and P. D. Shabanov, the peptide preparation “cortexin” and the synthetic tetrapeptide “cortagen” were reported to accelerate recovery of altered behavior in ischemic rats with varying levels of hypoxia tolerance (rats with high hypoxia tolerance and rats with low hypoxia tolerance). Furthermore, both peptides were associated with reduced lipid peroxidation and preservation of antioxidant activity in rat brain tissue. These findings relate to an experimental rat model and do not establish clinical efficacy or an indicated treatment for cerebral ischemia[2].
B. I. Kuznik reported that chickens hypophysectomized early in the neonatal period develop anemia, cellular and humoral immune deficiency, hypercoagulation and inhibited fibrinolysis by their 45th postnatal day. An analogous operation performed on old birds produces less significant changes in erythrocytes, immunity and hemostasis. In these avian experiments, epithalon tetrapeptide (Ala-Glu-Asp-Gly) was reported to reverse the measured changes in erythrocytes, immunity and hemostasis, whereas cortagene (Ala-Glu-Asp-Pro), which differs from epithalon by its terminal amino acid (Pro rather than Gly), did not affect the parameters studied[3].
Sergey V. Anisimov analyzed the expression of 15,247 transcripts in the hearts of 6-month-old female CBA mice in an experimental Cortagen-exposed group using cDNA microarrays. The study reported that a comparative analysis of cDNA microarray hybridization of heart samples from the control and experimental groups revealed that 234 clones (1.53% of the total number of clones) exhibited significant changes in expression, corresponding to 110 genes belonging to various known functional categories. The maximum upregulation and downregulation were +5.42 and -2.86, respectively[4].
L. N. Turchaninova’s research reported that Cortagen exposure in a rat model of sciatic nerve transection and suturing was associated with increased growth rate and conduction velocity of regenerating nerve fibers by 27% and 40%, respectively[5].
In situ hybridization performed by T. B. Kazakova on paraffin sections of rat brain reported changes in interleukin-2 gene expression associated with the synthetic peptides Vilon, Epithalon, and Cortagen in certain cells of the hypothalamus in vivo, under the experimental conditions examined[6].
Teimuraz Lezhava investigated the effects of the synthetic peptide bioregulator Cortagen on total heterochromatin, constitutive [pericentromeric, nucleolar organizer region (NOR)] heterochromatin, and facultative (transcription-inactive chromatin) heterochromatin. The researchers employed molecular cytogenetic methods: differential scanning calorimetry; ribosomal gene activity in the proximal centromeric chromosome satellite—NORs; polymorphism of structural pericentromeric C-heterochromatin; and variability of facultative heterochromatin (FH) in cultured lymphocytes from individuals aged 80 years and older. In these ex vivo lymphocyte cultures, the researchers reported that Cortagen was associated with changes in the organization of total heterochromatin and ribosomal gene activity near nucleolar organizer regions; no de-heterochromatinization of structural heterochromatin surrounding the centromere was reported; and changes involving facultative heterochromatin were observed[7].
Fig1. a Metaphases with Ag-positive acrocentric chromosomes association. b Frequency of acrocentric chromosomes association in Cortagen-treated lymphocyte cultures of aged individuals[7]. *p < 0.001
V. Kh. Khavinson’s study investigated the experimental effects of the synthetic peptides Vilon (Lys-Glu), Epithalon (Ala-Glu-Asp-Gly), and Cortagen (Ala-Glu-Asp-Pro), as well as the possible involvement of the sphingomyelin signal transduction pathway in their effects on mouse thymocytes. In the reported mouse thymocyte experiments, Vilon showed the strongest comitogenic effect on thymocyte proliferation and modulated the comitogenic activity of interleukin-1β. Epithalon was less potent, while Cortagen produced no such effects. Vilon produced a more pronounced stimulatory effect on sphingomyelinase activity in mouse thymocyte membranes compared to Epithalon and Cortagen[8].
Research Limitations
Although a tissue-specific mechanism for Cortagen has been proposed, its molecular basis remains unclear. The “cell-mediated” theory proposed by Khavinson’s team posits that peptides derived from specific tissues may influence responses in related tissue-derived experimental systems. However, it remains unresolved whether the proposed specificity arises from the conformational matching of peptide sequences with receptors on the surface of target cells or through nonspecific changes in membrane permeability that subsequently affect intracellular metabolism[9].
COCER Peptides presents Cortagen for laboratory research use only. It is not intended for human or veterinary administration, consumption, or any clinical use. The research discussed above summarizes findings reported in preclinical and ex vivo literature; these findings do not establish safety or efficacy in humans, and this document does not provide dosing or administration instructions. No FDA approval is claimed.
